Visual acuity gains seen in Vibrant study maintained beyond 24 weeks

SAN DIEGO — At week 52 of the Vibrant study, best corrected visual acuity letter score improved in a greater percentage of patients receiving intravitreal aflibercept injection than in patients undergoing laser treatment for branch retinal vein occlusion, according to a speaker here.Peter Campochiaro, MD, delivered updated findings of the study at the American Society of Retina Specialists annual meeting. The Vibrant study included 183 patients with center-involved macular edema secondary to branch retinal vein occlusion who were randomly assigned to undergo intravitreal injections with Eylea (aflibercept, Regeneron) or laser (Read more...)

Full Story →